Germany's Apceth Biopharma gets contract to manufacture EU-approved Zynteglo

apceth Biopharma
Germany CDMO Apceth Biopharma has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo. (apceth)

Germany’s Apceth Biopharma, a CDMO focused on cell and gene therapeutics, has won the contract to produce Bluebird Bio’s recently EU-approved Zynteglo.

The European Commission granted conditional marketing authorization Monday for Zynteglo, which is a gene therapy designed to treat transfusion-dependent β-thalassemia (TDT).

Zynteglo adds functional copies of an altered form of the β-globin gene into TDT patients’ own blood stem cells. The inserted genes then produce hemoglobin at normal levels, reducing or eliminating the need for the frequent blood transfusions that TDT patients generally receive.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“We are proud to be the commercial manufacturing partner of Bluebird Bio and to be part of bringing this life-changing therapy to TDT patients in Europe,” Christine Guenther, M.D., Apceth’s chief excecutive, said in a statement. “Being one of the very few companies worldwide to manufacture a cell-based gene therapy for commercial use marks a milestone for our company.”

Bluebird has said it expects to file for FDA approval of Zynteglo by the end of the year.

In April, Hitachi Chemical completed its $86.8 million acquisition of Apceth in a deal that gave the Japanese conglomerate two manufacturing sites in Munich with 6,458 square feet of cleanroom space.

Suggested Articles

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.

Turkey is getting its first locally produced mAb via an Iranian biosimilars marker and the $100 million plant it built there.